


## Ogremorphin

<b>Cat. No.:</b>	HY-154954		
<b>CAS No.:</b>	352563-21-4		
<b>Molecular Formula:</b>	C <sub>21</sub> H <sub>17</sub> N <sub>3</sub> OS		
<b>Molecular Weight:</b>	359.44		
<b>Target:</b>	GPR68		
<b>Pathway:</b>	GPCR/G Protein		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 50 mg/mL (139.11 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	<b>Preparing Stock Solutions</b>	1 mM	2.7821 mL	13.9105 mL	27.8211 mL
		5 mM	0.5564 mL	2.7821 mL	5.5642 mL
10 mM		0.2782 mL	1.3911 mL	2.7821 mL	
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 1.25 mg/mL (3.48 mM); Suspended solution; Need ultrasonic				

### BIOLOGICAL ACTIVITY

<b>Description</b>	Ogremorphin (GPR68-IN-1) is a potent GPR68 inhibitor with an EC <sub>50</sub> of 170 nM. Ogremorphin is extracted from patent WO2020214896 (OGM1), and can be used for autoimmune chronic inflammatory diseases research <sup>[1]</sup> .
--------------------	---

### REFERENCES

[1]. Charles C. Hong, et al. Small molecule inhibitors of gpcr gpr68 and related receptors. Patent WO2020214896.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA